Hvis resultaterne for lungekræft fra alle tre undersøgelser lægges sammen (480 patienter, der fik Hycamtin), var responsraten 20%.
In lung cancer, looking at the results obtained in all three studies, the response rate was 20% (480 patients received Hycamtin).